ArticleBMC biology2025
EnGCI: enhancing GPCR-compound interaction prediction via large molecular models and KAN network.
Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundIdentifying GPCR-compound interactions (GCI) plays a significant role in drug discovery and chemogenomics. Machine learning, particularly deep learning, has become increasingly influential in this domain. Large molecular models, due to their ability to capture detailed structural and functional information, have shown promise in enhancing the predictive accuracy of downstream tasks. Consequently, exploring the performance of these models in GCI prediction, as well as evaluating their effectiveness when integrated with other deep learning models, has emerged as a compelling research area. This paper aims to investigate these challenges.
resultsThis study introduces EnGCI, a novel model comprising two distinct modules. The MSBM integrates a graph isomorphism network (GIN) and a convolutional neural network (CNN) to extract features from GPCRs and compounds, respectively. These features are then processed by a Kolmogorov-Arnold network (KAN) for decision-making. The LMMBM utilizes two large-scale pre-trained models to extract features from compounds and GPCRs, and subsequently, KAN is again employed for decision-making. Each module leverages different sources of multimodal information, and their fusion enhances the overall accuracy of GPCR-compound interaction (GCI) prediction. Evaluating the EnGCI model on a rigorously curated GCI dataset, we achieved an AUC of approximately 0.89, significantly outperforming current state-of-the-art benchmark models.
conclusionsThe EnGCI model integrates two complementary modules: one that learns molecular features from scratch for the GPCR-compound interaction (GCI) prediction task, and another that extracts molecular features using pre-trained large molecular models. After further processing and integration, these multimodal information sources enable a more profound exploration and understanding of the complex interaction relationships between GPCRs and compounds. The EnGCI model offers a robust and efficient framework that enhances GCI predictive capabilities and has the potential to significantly contribute to GPCR drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.